EMA Authorised: Zynlonta (loncastuximab tesirine) — Swedish Orphan Biovitrum AB

View source ↗

Summary

The European Medicines Agency authorized Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and B-cell lymphoma, under a conditional marketing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse;Lymphoma, B-Cell. MAH: Swedish Orphan Biovitrum AB. Decision date: 24/10/2025. Conditional approval